Literature DB >> 2990104

Inhibition of HSV-transformed murine cells by nucleoside analogs, 2'-NDG and 2'-nor-cGMP: mechanisms of inhibition and reversal by exogenous nucleosides.

S Oliver, G Bubley, C Crumpacker.   

Abstract

A murine cell line transformed with HSV TK (LH-1) exhibits a greatly enhanced cytotoxicity to the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy) methyl]guanine (2'-NDG) as compared to the parental LM cell line (I50 LH-1 = 0.4 microM; I50 LM = 44.4 microM). Toxicity of 2'-NDG for LH-1 and LM is reversed only by the addition of 100 microM thymidine (dThd), indicating that 2'-NDG is a substrate for the viral and cellular TK. In LM(TK-) cells--murine cells expressing no TK activity, 2'-NDG cytotoxicity is partially reversed only with dGuo. A cyclic phosphate derivative of 2'-NDG, 2'-nor-cGMP, contains a phosphodiester bond, is also taken up by cells, and does not depend on viral TK for activation. LH-1 cells and LM(TK-) cells are inhibited by similar concentrations of this analog (5.1 and 4.1 microM, respectively). In all three cell lines (LM, LH-1, LM(TK-], the toxicity of 2'-nor-cGMP is significantly reversed with dGuo or cyclic dGMP. This pattern of reversal differs significantly from that observed with 2'-NDG, suggesting that 2'-nor-cGMP is metabolized as a guanosine analog, similar to acyclovir, in LM and LM(TK-) cells. These results indicate that a cyclic monophosphate analog of 2'-NDG can be activated independently of viral TK expression and that cellular metabolic pathways resulting in elevated dGTP concentrations are important for reversal of toxicity induced by guanosine-like nucleoside analogs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990104     DOI: 10.1016/0042-6822(85)90203-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

Review 1.  Imaging gene expression: principles and assays.

Authors:  S S Gambhir; J R Barrio; H R Herschman; M E Phelps
Journal:  J Nucl Cardiol       Date:  1999 Mar-Apr       Impact factor: 5.952

Review 2.  Advances in preclinical investigation of prostate cancer gene therapy.

Authors:  Marxa L Figueiredo; Chinghai Kao; Lily Wu
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

3.  Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information.

Authors:  M H St Clair; C U Lambe; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 4.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

5.  Comparison of the modes of antiviral action of 2'-nor-deoxyguanosine and its cyclic phosphate, 2'-nor-cyclic GMP.

Authors:  J Germershausen; R Bostedor; R Liou; A K Field; A F Wagner; M MacCoss; R L Tolman; J D Karkas
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

6.  Quantitative analysis of antiviral drug toxicity in proliferating cells.

Authors:  K Stenberg; J Wangenheim; B Tribukait
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

7.  DNA fragments binding CTCF in vitro and in vivo are capable of blocking enhancer activity.

Authors:  Dmitry A Didych; Elena S Kotova; Segey B Akopov; Lev G Nikolaev; Eugene D Sverdlov
Journal:  BMC Res Notes       Date:  2012-04-05

Review 8.  Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications.

Authors:  Timothy Y Chou; Bennett Y Hong
Journal:  Ther Clin Risk Manag       Date:  2014-08-20       Impact factor: 2.423

9.  Synergistic effect of resveratrol and HSV-TK/GCV therapy on murine hepatoma cells.

Authors:  Jianyong Xiao; Xiaolan Wang; Yingya Wu; Qing Zhao; Xiaodong Liu; Guangxian Zhang; Zengqiang Zhao; Yizhen Ning; Kun Wang; Yuhui Tan; Biaoyan Du
Journal:  Cancer Biol Ther       Date:  2018-09-26       Impact factor: 4.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.